Burgdorf - Ypsomed (SIX: YPSN) has developed a new autoinjector platform for liquid medications with volumes ranging from 1.5 to 5.5 ml. The YpsoMate 5.5 is the latest addition to the growing YpsoMate family of devices and is based on the established technology of the YpsoMate 2.25 Pro. YpsoMate 5.5 enables the self-administration of larger volume medications for treating cancer, rare and autoimmune diseases.
YpsoMate 5.5
With the increasing use of therapeutic proteins administered subcutaneously, the use of autoinjectors has steadily increased in recent years and continues to rise. Self-medication makes daily life easier for many people with chronic diseases and reduces the burden on the healthcare system. Thanks to easy-to-use self-injection systems such as the YpsoMate autoinjector with pre-filled syringe, patients can treat themselves at home instead of visiting a medical facility to do so. Larger dosing volumes can reduce the number of injections required, further reducing the treatment burden for patients and caregivers.
Making selfcare simpler and easier
YpsoMate 5.5 represents the newest member of the YpsoMate autoinjector family and expands the application range of current autoinjectors by enabling the administration of larger volumes in the range of 2.0 to 5.5 ml from a pre-filled syringe. We are setting a new standard for self-management of chronic diseases,
says Ulrike Bauer, Chief Business Officer Delivery Systems at Ypsomed.
Product design promotes easy and safe handling
Simplicity and safe handling are crucial. The YpsoMate 5.5 features the two-step handling already well proven in YpsoMate models: Removing the cap and pushing on the skin. The injection process is triggered automatically. During product design, special focus was placed on providing optimal support for larger volumes and a longer injection duration. The YpsoMate 5.5 is equipped with a handgrip that allows comfor-table handling and a stable hand position during injection. A continuous visual and audible signal gives the user good control over the entire injection process.
Ready-to-use syringe in collaboration with Schott Pharma
The YpsoMate 5.5 features an integrated, pre-filled syringe developed in collaboration with Schott, a leading manufacturer of storage and delivery systems for medicines. It leverages existing standards and components to optimize processes for pharmaceutical customers and shorten time-to-market, reduce development risks, ensure suitability for sensitive drugs and facilitate compatibility with existing filling equipment. The result of the joint development is the syriQ BioPure 5.5 mL, a large-volume, prefillable syringe with integrated needle.
Ypsomed Holding AG published this content on 17 October 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 October 2022 05:12:01 UTC.
Ypsomed Holding AG is a Switzerland-based holding company engaged in the manufacture of injection pens for pharmaceutical and biotech companies. The Company develops and manufactures injection systems for custom-made self-administration, and markets pen needles for the treatment of diabetes, growth disorders or infertility, as well as therapeutic areas. The Company operates two business segments: Injection Systems and Diabetes Care. In the Injection Systems segment, the Company's YDS Ypsomed Delivery Systems offer a range of ready-to-use injection systems for pharmaceutical and biotech companies to administer of drugs or to develop and manufacture them in line with customer requirements. The Diabetes Care segment markets products such as pen needles or insulin pump to diabetics, doctors and health insurance providers. The Company operates its production sites in Burgdorf, Solothurn, Grenchen and Tabor, and sales and distribution network across Europe.
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
